Please login to the form below

Not currently logged in

AbbVie and Roche hoping for speedy venetoclax approval

Leukaemia treatment could reach US and EU markets within months

AbbVie and Roche's investigational BCL-2 inhibitor venetoclax could be on the market within the next few months after US and EU regulators kicked off reviews of the new drug.

The two partners confirmed that the US FDA has granted a priority review to venetoclax as a second-line treatment for adults with chronic lymphocytic leukaemia (CLL) associated with a 17p deletion, setting up possible approval of the first-in-class drug within six months.

Meanwhile, in Europe the EMA has started a standard review for the drug as a treatment for patients with CLL associated with either a 17p deletion of TP53 mutation.

CLL is a slow-progressing cancer of the bone marrow and blood and is the most common leukaemia diagnosed in adults in western countries.

The marketing applications for the drug are based largely on the results of the phase II M13-982 study, which involved 157 patients with relapsed, refractory or previously untreated CLL with 17p deletion.

Data presented in December showed a clinically meaningful reduction in the number of cancer cells (an overall response rate or ORR) in 79% of patients, with no unexpected safety signals recorded.

All told, 7.5% of subjects on venetoclax treatment achieved a complete response, and in a few individuals intensive tests revealed no malignant cells in either the blood or bone marrow.

Last May, the FDA awarded breakthrough therapy status to venetoclax for the treatment of CLL in patients with the p17 deletion, which is present in between 3% and 10% of all CLL patients but is disproportionately found in relapsed and refractory cases.

If approved, venetoclax will compete in the market with other new therapies for CLL, including Johnson & Johnson's first-in-class BTK inhibitor Imbruvica (ibrutinib) and Gilead Sciences' Zydelig (idelalisib), which were both given a green light in 2014.

Venetoclax is also mid-stage trials for several other cancer types, including non-Hodgkin's lymphoma (NHL), acute myeloid leukaemia and multiple myeloma, and is due to start combination trials with Imbruvica and Roche's Gazyva (obinutuzumab) which was approved for first-line CLL therapy alongside chemotherapy in 2013.

Article by
Phil Taylor

13th January 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...